<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809182</url>
  </required_header>
  <id_info>
    <org_study_id>Dexmedetomidine and glycemia</org_study_id>
    <nct_id>NCT03809182</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels</brief_title>
  <official_title>Effect of Dexmedetomidine on Postoperative Glucose Levels and Insulin Secretion Patterns in Obese Patients With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the effect of dexmedetomidine in obese patients undergoing bariatric
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, double-blind, randomized controlled trial was performed. Consenting obese
      adults patients with impaired glucose tolerance, undergoing bariatric surgery, were
      randomized, by a computer, to receive placebo (0.9% Sodium-chloride) or dexmedetomidine 1
      ug/kg bolus in 10 minutes followed by an infusion of 0.5 ug/kg/h until the end of surgery.
      Baseline HgbA1c, glucose, and insulin plasmatic levels were measured. Subsequently, glucose
      and insulin levels were taken every 2 hours during the first 12 hours from the onset of the
      drug infusion. Intraoperative fentanyl and postoperative morphine consumption, pain score,
      the occurrence of emesis, and postoperative sedation levels were recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2013</start_date>
  <completion_date type="Actual">February 1, 2014</completion_date>
  <primary_completion_date type="Actual">February 1, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of baseline glucose levels within the first 12 postoperative hours.</measure>
    <time_frame>Baseline levels(T0) and at hour 2(T1), 4(T2), 6(T3), 8(T4), 10(T5), and 12(T6) after the onset of bolus and infusion of dexmedetomidine</time_frame>
    <description>Glucose levels (mg/dl).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of baseline insulin levels within the first 12 postoperative hours.</measure>
    <time_frame>Baseline levels(T0) and at hour 2(T1), 4(T2), 6(T3), 8(T4), 10(T5), and 12(T6) after the onset of bolus and infusion of dexmedetomidine</time_frame>
    <description>Insulin levels (uU/ml).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fentanyl consumption.</measure>
    <time_frame>Intraoperative period.</time_frame>
    <description>Amount (ug) of fentanyl intraoperatively administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption in the first 24 postoperative hours.</measure>
    <time_frame>At postoperative hours 2(T1), 4(T2), 6(T3), 8(T4), 10(T5), 12(T6) and 24(T7).</time_frame>
    <description>Amount (mg) of morphine consumed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores in the first 24 postoperative hours.</measure>
    <time_frame>At postoperative hours 2(T1), 4(T2), 6(T3), 8(T4), 10(T5), 12(T6) and 24(T7).</time_frame>
    <description>Visual analogue scale (VAS), provided by patients, ranging from 0 to 10 (0= no pain and 10= worst possible pain). We considered a pain score between 1-3, 4-6 and 7-10 as mild, moderate and severe pain, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation-agitation scores in the first 12 postoperative hours.</measure>
    <time_frame>At postoperative hours 2(T1), 4(T2), 6(T3), 8(T4), 10(T5) and 12(T6).</time_frame>
    <description>Riker sedation-agitation scale (SAS), ranging from 1 to 7 (1=unarousable, 2=very sedated, 3=sedated, 4=calm and cooperative, 5=agitated, 6=very agitated and 7=dangerous agitation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with postoperative nausea and vomiting in the first 24 postoperative hours.</measure>
    <time_frame>At postoperative hours 2(T1), 4(T2), 6(T3), 8(T4), 10(T5), 12(T6) and 24(T7).</time_frame>
    <description>Postoperative nausea and vomiting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Glucose Intolerance</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After anesthesia induction, patients who were randomized to the Dexmedetomidine group, received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/min until the end of surgery. In case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Sodium-chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium-chloride</intervention_name>
    <description>The same dose used in the dexmedetomidine group (bolus and infusion).</description>
    <arm_group_label>0.9% Sodium-chloride</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).</description>
    <arm_group_label>0.9% Sodium-chloride</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Sublimaze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 a patient-controlled analgesia pumps were installed and the patients were discharged to their room.</description>
    <arm_group_label>0.9% Sodium-chloride</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese patient (BMI&gt;30)

          -  American Society of Anesthesiologists grades II or III

          -  Diagnosis of impaired glucose tolerance

          -  Undergoing sleeve gastrectomy

        Exclusion Criteria:

          -  Baseline glucose &gt; 200mg/dl

          -  Diagnosis of Diabetes

          -  Under corticosteroids treatment

          -  Oral hypoglycemic medication within 7 days previous surgery

          -  Use of insulin within 24h previous surgery

          -  Allergy to any drug used in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Ibacache, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 30, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontificia Universidad Catolica de Chile</investigator_affiliation>
    <investigator_full_name>Eduardo Vega</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>Obese patients</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03809182/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03809182/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>December 8, 2019</submitted>
    <submission_canceled>December 10, 2019</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

